BDC2.5 Mimotope 1040-63

Human pluripotent stem cell pancreatic β-cell/islet-like differentiation is a staged directed-differentiation method that models embryonic progression from pluripotency to definitive endoderm, primitive gut tube/posterior foregut, pancreatic endoderm or pancreatic progenitors, endocrine progenitors, and β-like/islet-like endocrine cells. The principal readouts are sequential acquisition of lineage markers: SOX17/FOXA2 for definitive endoderm, PDX1 and NKX6. 1 for pancreatic progenitors, NEUROG3 for endocrine progenitors, and insulin/C-peptide with β-cell markers such as NKX6. 1 and MAFA for β-like cells. Functional readouts include glucose-stimulated insulin or C-peptide secretion, dynamic perifusion responses, calcium signaling, mitochondrial activity, and reversal or improvement of hyperglycemia after transplantation in diabetic immunodeficient mice when tested.

Transgenic overexpression models are generated by introducing an exogenous DNA construct containing a gene of interest into the germline or early embryo so that the transgene integrates into the host genome and is stably expressed under the control of a chosen promoter, enabling in vivo analysis of gene function and disease mechanisms. The most established strategy is pronuclear microinjection of linearized DNA into fertilized oocytes, followed by random genomic integration and germline transmission, which allows constitutive or tissue-specific overexpression depending on promoter selection. Alternative strategies include viral vector-mediated gene delivery (e. g. , lentiviral systems) and transposon-based integration systems, which improve efficiency of stable genomic insertion in certain contexts. These approaches collectively enable functional gain-of-function studies in vivo across multiple organ systems and disease models.

Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.

The method of preserving islets in vitro, with purified reduced immunogenicity. The steps are islet isolation, islet cell purification, in vitro determination of islet function and islet cell culture.

AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked

Cancer immunology studies how the immune system recognizes, suppresses, edits, or fails to eliminate malignant cells through tumor antigen release, antigen presentation, T-cell priming, immune trafficking, tumor-cell killing, and feedback inhibition in the tumor microenvironment. The cancer-immunity cycle links tumor antigenicity, dendritic-cell priming, CD8+ T-cell infiltration, cytotoxic function, and immune-checkpoint regulation to tumor rejection or immune escape. Immune-checkpoint pathways such as PD-1/PD-L1 and CTLA-4 suppress antitumor T-cell activity and can be therapeutically blocked, but many tumors remain resistant because of poor antigen presentation, weak T-cell infiltration, suppressive myeloid cells, regulatory T cells, and tumor-intrinsic immune-exclusion programs. Unresolved questions include which immune-cell states predict response, how tumor-intrinsic pathways exclude immune cells, how myeloid suppression limits checkpoint blockade, and which combination strategies